Updates to our Terms of Use

We are updating our Terms of Use. Please carefully review the updated Terms before proceeding to our website.

Friday, July 19, 2024 | Back issues
Courthouse News Service Courthouse News Service

Japan team carries out world-first spinal cord stem cell trial

Keio University has been studying whether injuries with no known cure can be treated with stem cells that are already mature and specialized cells but stimulated back into a juvenile state.

TOKYO (AFP) — A Japanese university said Friday it has successfully transplanted stem cells into a patient with a spinal cord injury, in the first clinical trial of its kind.

There is currently no effective treatment for paralysis caused by serious spinal cord injuries, believed to affect more than 100,000 people in Japan alone.

Surgeons at Tokyo's Keio University want to study whether induced pluripotent stem (iPS) cells can be used to treat the injuries.

iPS cells are created by stimulating mature, already specialized, cells back into a juvenile state.

They can then be prompted to mature into different kinds of cells, with the Keio University study using iPS-derived cells of the neural stem.

The first step in the trial involved implanting more than 2 million iPS-derived cells into a patient's spinal cord in an operation last month.

"This is definitely a huge step forward," Masaya Nakamura, a Keio University professor who heads the research, told reporters.

But there remains "lots of work to be done" before the treatment can be put to use, he added.

The initial stage of the study aims to confirm the safety of the transplant method, the researchers said.

The patient will be monitored by an independent committee for up to three months to decide whether the study can safely continue and others can receive transplants.

The team also hopes to see whether the stem cell implants will improve neurological function and quality of life.

The university received government approval for the trial in 2019, but recruitment was temporarily put on hold because of the Covid-19 pandemic.

Details of the patients remain confidential, but the team is focusing on people who were injured 14-28 days before the operation.

The number of cells implanted was determined after safety experiments in animals, and the researchers cautioned that while they will be monitoring for therapeutic effects, the study's main goal is to study the safety of injecting the cells.


by Tomohiro OSAKI
© Agence France-Presse

Categories / Health, International, Science

Subscribe to Closing Arguments

Sign up for new weekly newsletter Closing Arguments to get the latest about ongoing trials, major litigation and hot cases and rulings in courthouses around the U.S. and the world.